Safety and Efficacy of Ferric Carboxymaltose in Comparison with Iron Sucrose for the Management of Iron Deficiency Anaemia in Pregnant Patients Presenting at a Tertiary Care Hospital in Lahore

Abstract

Objective: To compare the safety profile and determine the efficacy of ferric carboxymaltose with iron sucrose in pregnant patients with iron deficiency anemia
Material and Methods: This comparative study was conducted at Central Park Teaching Hospital from 1st January 2023 to 30th June 2023. A hundred women from 16 to 36 weeks of gestation presenting with iron deficiency anemia who fulfilled the inclusion criteria were enrolled and randomized into groups. They were infused with Iron sucrose (IS) or ferric carboxymaltose (FCM) as per the calculated dose. Adverse effects were noted, hemoglobin was measured after 3 weeks, and data was analyzed statistically.
Results: The mean pre-treatment haemoglobin in IS group was 8.71
Conclusion: This study concludes that ferric carboxymaltose is a drug with more efficacy and safer than
intravenous iron sucrose for the treatment of iron deficiency anemia in pregnant women.
Keywords: Ferric carboxymaltose, Iron sucrose, Iron deficiency Anemia, Intravenous iron therapy